As September draws to a close, Keeping Track is now looking closely at October, which will bring two biosimilar application user fee goals. With anticipation for biosimilar insulin growing, FDA approved two long-acting insulin analogs as new molecular entities.
Interim data from Novo Nordisk AS's DEVOTE cardiovascular outcomes trial for its long-acting insulin analog insulin degludec sufficed to assuage FDA concerns about CV risk with antidiabetics, and insulin degludec was approved as single-agent Tresiba and in
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?